Anti-glomerular basement membrane nephritis Medical Services in China

Anti-glomerular basement membrane (anti-GBM) nephritis, also known as Goodpasture syndrome when accompanied by pulmonary hemorrhage, is a rare, life-threatening autoimmune disorder characterized by the production of pathogenic IgG autoantibodies targeting the non-collagenous domain (NC1) of the alpha-3 chain of type IV collagen in the glomerular and alveolar basement membranes. This antibody binding triggers complement activation, neutrophil recruitment, and subsequent inflammatory destruction of glomeruli—leading to rapidly progressive glomerulonephritis (RPGN)—and, in ~60% of cases, concurrent diffuse alveolar hemorrhage. Pathogenesis centers on loss of immune tolerance, often precipitated by environmental exposures (e.g., tobacco smoke, hydrocarbon inhalants, viral upper respiratory infections) in genetically susceptible individuals—particularly those carrying HLA-DRB1*15:01 or *15:02 alleles. The disease exhibits a bimodal age distribution: young adults (20–30 years) and older adults (>60 years), with a slight male predominance. Its annual incidence is approximately 0.5–1.0 per million population globally, making it exceptionally rare; prevalence is estimated at 5–10 per million. Risk factors include smoking (strongest modifiable risk), prior respiratory insults (e.g., influenza, vaping), exposure to organic solvents, and certain genetic polymorphisms affecting antigen presentation and B-cell regulation. Notably, anti-GBM disease rarely occurs post-kidney transplantation in patients with prior anti-GBM disease due to recurrence risk. Clinically, patients present acutely with hematuria, proteinuria, rapid decline in eGFR (often progressing to dialysis-dependent kidney failure within days to weeks), fatigue, hypertension, and—when pulmonary involvement exists—cough, dyspnea, hemoptysis, and hypoxemia. Without prompt intervention, mortality exceeds 80%, primarily from respiratory failure or end-stage kidney disease. Even with aggressive therapy, up to 70% of patients require long-term dialysis or kidney transplantation, and 30–40% experience permanent renal impairment. Quality of life is profoundly impacted: patients face chronic fatigue, dietary and fluid restrictions, frequent clinic visits, immunosuppression-related complications (e.g., infections, diabetes, osteoporosis), psychological burden (anxiety, depression), and socioeconomic strain from treatment costs and work disability. Survivors often require lifelong nephrology follow-up, anemia management, cardiovascular risk mitigation, and psychosocial support. Early diagnosis—via serum anti-GBM antibody testing and confirmatory renal biopsy showing linear IgG deposition along GBM—is critical for timely plasma exchange and immunosuppression, which remain the cornerstone of survival and renal preservation.

Anti-glomerular basement membrane (anti-GBM) nephritis, also known as Goodpasture syndrome when accompanied by pulmonary hemorrhage, is a rare, life-threatening autoimmune disorder characterized by autoantibodies targeting the non-collagenous domain (NC1) of the alpha-3 chain of type IV collagen in the glomerular and alveolar basement membranes. Prompt diagnosis and aggressive immunosuppression are critical to preserving renal function and preventing irreversible damage. Management requires a multidisciplinary approach coordinated by nephrologists, pulmonologists, and critical care specialists.

Conservative treatment forms the essential supportive backbone of management but is never sufficient alone. It includes strict blood pressure control—typically targeting <130/80 mmHg using angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), provided serum creatinine remains stable and hyperkalemia is absent. Fluid and electrolyte balance must be meticulously monitored; diuretics may be required for volume overload, while sodium and potassium restriction is often necessary in advanced disease. Nutritional support is vital: a low-protein, low-sodium, low-phosphorus diet is recommended in patients with significant proteinuria or declining GFR, though protein intake should not fall below 0.6–0.8 g/kg/day to prevent catabolism. Anemia management includes erythropoiesis-stimulating agents (ESAs) and iron supplementation if ferritin <100 ng/mL and transferrin saturation <20%. In cases of severe anemia or active pulmonary hemorrhage, packed red blood cell transfusions may be indicated—but only after confirming hemodynamic stability and absence of ongoing bleeding, given the risk of volume overload and hypertension-induced capillary stress.

Pharmacologic therapy is the cornerstone of disease-specific intervention. First-line treatment consists of triple immunosuppression: high-dose intravenous methylprednisolone (7–15 mg/kg/day, up to 1 g daily for 3 days), followed by oral prednisone (1 mg/kg/day, tapered over 3–6 months); cyclophosphamide (2–3 mg/kg/day orally or IV pulse dosing every 2–4 weeks); and urgent plasma exchange (PLEX). PLEX is initiated within 24 hours of diagnosis—typically 40–60 mL/kg per session, performed daily for 14 consecutive days or until anti-GBM antibody titers become undetectable (usually requiring ≥10–14 sessions). Each session removes circulating pathogenic IgG antibodies and inflammatory mediators. Rituximab (375 mg/m² weekly × 4 doses or 1 g × 2 doses two weeks apart) is increasingly used as a steroid-sparing and cyclophosphamide-sparing alternative, particularly in patients with contraindications to alkylating agents (e.g., fertility concerns, prior malignancy, or severe leukopenia). Emerging evidence supports its efficacy in inducing remission and reducing relapse risk, especially when combined with PLEX and corticosteroids. For refractory or relapsing disease, mycophenolate mofetil or azathioprine may serve as maintenance agents following induction, though data remain limited. Antibiotic prophylaxis (e.g., trimethoprim-sulfamethoxazole) is routinely administered during cyclophosphamide therapy to prevent *Pneumocystis jirovecii* pneumonia.

Surgical treatment plays a highly circumscribed role. Kidney transplantation is contraindicated during active disease and requires sustained seronegativity (>12 months off immunosuppression) and stable extra-renal manifestations before consideration. Transplantation carries a 10–15% risk of anti-GBM antibody recurrence, necessitating lifelong monitoring of antibody titers and prompt re-initiation of PLEX if detected. In rare cases of catastrophic pulmonary hemorrhage unresponsive to medical therapy, bronchial artery embolization may be employed emergently to control localized bleeding. However, this is palliative—not curative—and does not address underlying autoimmunity. Surgical nephrectomy has no role in anti-GBM disease and is strictly avoided, as it neither halts antibody production nor improves outcomes.

China offers distinct advantages in the comprehensive management of anti-GBM nephritis. First, national standardization of PLEX protocols across Class III Grade A hospitals ensures rapid access to high-volume, experienced apheresis centers—many equipped with automated centrifugal or membrane-based systems enabling precise IgG removal with minimal albumin loss. Second, China’s robust domestic biopharmaceutical industry provides timely, cost-effective access to rituximab, cyclophosphamide, and biosimilar monoclonal antibodies, reducing financial toxicity and improving adherence. Third, integrated traditional Chinese medicine (TCM) adjuncts—such as *Tripterygium wilfordii* glycosides (used under strict hepatorenal monitoring) or *Salvia miltiorrhiza*-based formulations—are increasingly incorporated into maintenance regimens in clinical trials, demonstrating potential synergistic anti-inflammatory and antifibrotic effects without compromising immunosuppressive efficacy. Fourth, China’s centralized electronic health record system facilitates longitudinal antibody titer tracking, real-time inter-hospital consultation via tele-nephrology platforms, and AI-assisted risk stratification models that predict progression to ESKD with >85% sensitivity. Finally, large-scale multicenter registries (e.g., the China Anti-GBM Registry) enable rapid evidence generation and protocol refinement tailored to East Asian phenotypes—including higher prevalence of isolated renal involvement and lower incidence of pulmonary hemorrhage compared to Western cohorts.

Recovery advice emphasizes long-term vigilance and lifestyle integration. Patients must undergo quarterly clinical assessments—including serum creatinine, eGFR, urinalysis, and quantitative anti-GBM antibody testing—for at least two years post-remission. Annual chest imaging (low-dose CT) is advised for those with prior pulmonary involvement. Vaccination status must be optimized: influenza, pneumococcal, hepatitis B, and COVID-19 vaccines are strongly recommended—though live vaccines (e.g., varicella, MMR) are contraindicated during active immunosuppression. Smoking cessation is non-negotiable, given its potent pro-inflammatory and endothelial-damaging effects. Physical activity should be gradually resumed—starting with supervised aerobic exercise (e.g., walking 30 min/day, 5×/week)—to improve cardiovascular fitness and mitigate steroid-induced myopathy. Psychosocial support is integral: depression and anxiety affect >40% of survivors, warranting routine screening and referral to mental health services. Female patients of childbearing age require preconception counseling regarding teratogenic risks of cyclophosphamide and optimal timing for pregnancy (ideally ≥12 months after discontinuation of all immunosuppressants and confirmed seronegativity). Finally, patients must be educated to recognize early relapse symptoms—such as new-onset hemoptysis, dyspnea, fatigue, or dark urine—and seek immediate evaluation. With timely, protocol-driven care, 5-year patient survival exceeds 85% in specialized centers, and nearly 50% of patients with baseline creatinine <5.6 mg/dL avoid dialysis dependence.